181 related articles for article (PubMed ID: 37005217)
1. Carcinoid heart disease in patients with midgut neuroendocrine tumours.
Delhomme C; Walter T; Arangalage D; Suc G; Hentic O; Cachier A; Alkhoder S; François L; Lombard-Bohas C; Iung B; Ruszniewski P; de Mestier L
J Neuroendocrinol; 2023 Apr; 35(4):e13262. PubMed ID: 37005217
[TBL] [Abstract][Full Text] [Related]
2. Carcinoid heart disease--a hidden complication of neuroendocrine tumours.
Dero I; De Pauw M; Borbath I; Delaunoit T; Demetter P; Demolin G; Hendlisz A; Pattyn P; Pauwels S; Roeyen G; Van Cutsem E; Van Hootegem P; Van Laethem JL; Verslype C; Peeters M
Acta Gastroenterol Belg; 2009; 72(1):34-8. PubMed ID: 19402369
[TBL] [Abstract][Full Text] [Related]
3. Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours.
Kostiainen I; Karppinen N; Simonen P; Rosengård-Bärlund M; Lindén R; Tarkkanen M; Gordin D; Rapola J; Schalin-Jäntti C; Matikainen N
Endocrine; 2022 Jun; 77(1):177-187. PubMed ID: 35536452
[TBL] [Abstract][Full Text] [Related]
4. What do we know about carcinoid heart disease in the present era?
Pęczkowska M; Konsek-Komorowska SJ; Kolasińska-Ćwikła AD; Konka M; Michałowska I; Ćwikła JB
Kardiol Pol; 2022; 80(10):990-1001. PubMed ID: 36136036
[TBL] [Abstract][Full Text] [Related]
5. Update in carcinoid heart disease - the heart of the matter.
Oleinikov K; Korach A; Planer D; Gilon D; Grozinsky-Glasberg S
Rev Endocr Metab Disord; 2021 Sep; 22(3):553-561. PubMed ID: 33443717
[TBL] [Abstract][Full Text] [Related]
6. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study.
Lesén E; Björstad Å; Björholt I; Marlow T; Bollano E; Feuilly M; Marteau F; Welin S; Elf AK; Johanson V
Scand J Gastroenterol; 2018 Dec; 53(12):1509-1518. PubMed ID: 30449217
[TBL] [Abstract][Full Text] [Related]
7. Carcinoid Heart Disease: From Pathophysiology to Treatment--'Something in the Way It Moves'.
Grozinsky-Glasberg S; Grossman AB; Gross DJ
Neuroendocrinology; 2015; 101(4):263-73. PubMed ID: 25871411
[TBL] [Abstract][Full Text] [Related]
8. Managing carcinoid heart disease in patients with neuroendocrine tumors.
Koffas A; Toumpanakis C
Ann Endocrinol (Paris); 2021 Jun; 82(3-4):187-192. PubMed ID: 33321109
[TBL] [Abstract][Full Text] [Related]
9. Carcinoid Heart Disease: Pathophysiology, Pathology, Clinical Manifestations, and Management.
Jin C; Sharma AN; Thevakumar B; Majid M; Al Chalaby S; Takahashi N; Tanious A; Arockiam AD; Beri N; Amsterdam EA
Cardiology; 2021; 146(1):65-73. PubMed ID: 33070143
[TBL] [Abstract][Full Text] [Related]
10. Echocardiography in functional midgut neuroendocrine tumors: When and how often.
Castillo JG; Naib T; Zacks JS; Adams DH
Rev Endocr Metab Disord; 2017 Dec; 18(4):411-421. PubMed ID: 29080935
[TBL] [Abstract][Full Text] [Related]
11. Variation in Cardiac Screening and Management of Carcinoid Heart Disease in the UK and Republic of Ireland.
Dobson R; Valle JW; Burgess MI; Poston GJ; Cuthbertson DJ
Clin Oncol (R Coll Radiol); 2015 Dec; 27(12):741-6. PubMed ID: 26170123
[TBL] [Abstract][Full Text] [Related]
12. Management and outcomes of carcinoid heart disease with liver metastases of midgut neuroendocrine tumours.
Suc G; Cachier A; Hentic O; Bazire B; Sannier A; Delhomme C; Nataf P; Laschet J; Deschamps L; Garbarz E; Ou P; Caligiuri G; Iung B; Ruszniewski P; de Mestier L; Arangalage D
Heart; 2023 Dec; 110(2):132-139. PubMed ID: 37463732
[TBL] [Abstract][Full Text] [Related]
13. Four decades of experience with carcinoid heart disease: An analysis of 84 patients.
Levy S; Korse CE; de Groot ACA; Meijer RCA; Tesselaar MET; Valk GD
J Neuroendocrinol; 2022 Oct; 34(10):e13199. PubMed ID: 36256859
[TBL] [Abstract][Full Text] [Related]
14. Carcinoid Heart Disease: a Review.
Laskaratos FM; Davar J; Toumpanakis C
Curr Oncol Rep; 2021 Mar; 23(4):48. PubMed ID: 33725214
[TBL] [Abstract][Full Text] [Related]
15. Carcinoid Heart Disease: A Review.
Hayes AR; Davar J; Caplin ME
Endocrinol Metab Clin North Am; 2018 Sep; 47(3):671-682. PubMed ID: 30098723
[TBL] [Abstract][Full Text] [Related]
16. Carcinoid Heart Disease: a Comprehensive Review.
Hassan SA; Palaskas NL; Agha AM; Iliescu C; Lopez-Mattei J; Chen C; Zheng H; Yusuf SW
Curr Cardiol Rep; 2019 Nov; 21(11):140. PubMed ID: 31745664
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin A (CgA) as a biomarker in carcinoid heart disease and NETG1/G2 neuroendocrine neoplasms of the small intestine (SI-NENs) related carcinoid syndrome.
Konsek-Komorowska SJ; Pęczkowska M; Kolasińska-Ćwikła AD; Konka M; Chrapowicki E; Ćwikła JB
Med Clin (Barc); 2022 Jul; 159(2):85-89. PubMed ID: 34736622
[TBL] [Abstract][Full Text] [Related]
18. Multidisciplinary team management of carcinoid heart disease.
Steeds R; Sagar V; Shetty S; Oelofse T; Singh H; Ahmad R; Bradley E; Moore R; Vickrage S; Smith S; Yim I; Elhassan YS; Venkataraman H; Ayuk J; Rooney S; Shah T
Endocr Connect; 2019 Dec; 8(12):R184-R199. PubMed ID: 31751305
[TBL] [Abstract][Full Text] [Related]
19. Current Practice in Carcinoid Heart Disease and Burgeoning Opportunities.
Lenneman C; Harrison D; Davis SL; Kondapalli L
Curr Treat Options Oncol; 2022 Dec; 23(12):1793-1803. PubMed ID: 36417147
[TBL] [Abstract][Full Text] [Related]
20. Carcinoid Syndrome and Carcinoid Heart Disease as Manifestations of Non-Metastatic Ovarian Neuroendocrine Tumour.
Simões-Pereira J; Wang LM; Kardos A; Grossman A
Acta Med Port; 2017 May; 30(5):421-425. PubMed ID: 28865508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
